Spinraza (nusinersen) - Biogen
Exondys 51 (eteplirsen) - Sarepta Therapeutics
WVE-120102 - Wave Life Sciences, Takeda
WVE-120101 - Wave Life Sciences, Takeda
tominersen (RG6042) - Roche
Development of Antisense Gapmers for the Treatment of Huntington's Disease. (PubMed, Methods Mol Biol) - Oct 1, 2026 - "Antisense-mediated knockdown of mutated huntingtin is a promising therapeutic approach for Huntington's disease (HD), a devastating disorder affecting motor and cognitive abilities. This chapter focuses on the modified gapmer AOs for the treatment of HD." 
Journal • CNS Disorders • Huntington's Disease • Movement Disorders
http://www.ncbi.nlm.nih.gov/pubmed/42814297
 
Tejal Aslesh; Toshifumi Yokota
 
Oct 1, 2026
 
Prev Next